Center for Applied Genomics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USAUnit on Vascular Malformations, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USAComprehensive Vascular Anomalies Program, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies - Nature MedicineA modified seed aggregation assay detects minute amounts of serum α-synuclein seeds in individuals with Synucleinopathy, demonstrating high performance as a DiagnosticBiomarker.
Source: NatureMedicine - 🏆 451. / 53 Read more »
A call to invest in emergency, critical and operative care for universal health coverageA call to invest in emergency, critical and operative care for universal health coverage at WHA72. Correspondence from Ministers of Health lia_tadesse, nsanzimanasabin, Ahmadou Lamin Samateh, Ali Haji Adam Abubakar, DrZalihaMustafa and colleagues
Source: NatureMedicine - 🏆 451. / 53 Read more »
Baylor College of Medicine breaks ground on education buildingReal estate roundup: Baylor College of Medicine starts new education building near Texas Medical Center
Source: HoustonChron - 🏆 609. / 51 Read more »
Eskanzi Health and IU School of Medicine partner to help fight food insecurityEskenazi Health and IU School of Medicine are teaming up to help fight food insecurity by targeting patients with high blood pressure and showing them how to cook healthy, affordable meals.
Source: wrtv - 🏆 598. / 51 Read more »
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation - Nature MedicineIn a study of two children with the metabolic condition D-2-hydroxyglutaric aciduria type II, the drug enasidenib, developed as a selective mutant IDH2 inhibitor for treatment of acute myeloid leukemia, had beneficial effects on cardiac and neurodevelopmental abnormalities, indicating the potential for the repurposing of this drug for this hereditary condition.
Source: NatureMedicine - 🏆 451. / 53 Read more »